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IMPACT OF WALKING AND MOBILITY PROBLEMS ON REQUIREMENT FOR
HEALTHCARE AMONG MULTIPLE SCLEROSIS PATIENTS
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1Biogen Idec, Wellesley, MA, USA, 2Adelphi Real World, Macclesfield, Cheshire, UK
BACKGROUND: Multiple sclerosis (MS) is a chronic, progressive disease, often ac-
companied by functional impairment due to walking/mobility problems (WMPs).
The impact of WMPs on the use of direct healthcare resources therefore warrants
further study. OBJECTIVES: Investigate the relationship between presence and
severity of WMPs and hospitalisation, physician consultations, time with allied
healthcare professionals and mobility aids.METHODS: Data were obtained from a
cross-sectional study of 340 neurologists in France, Germany, Italy, Spain and the
UK. Neurologists completed records on the next 10-12 consulting MS patients. Of
the total 3572 patients, 2111 completed a questionnaire indicating their level of
WMPs: none (n1342), mild (n271), moderate (n314), or severe (n184). ANOVA
with Bonferroni-corrected t-tests were used to assess the relationship between
WMPs and physician-reported data on hospital episodes, physician consultations,
and healthcare professional time. Patient support, including use of mobility aids,
was analyzed using Chi-square with Bonferroni-adjusted Fisher’s-Exact tests.
RESULTS: A positive association between healthcare utilisation and increased se-
verity of WMPs was observed. Number of hospitalisations in the past 12 months
increased from 0.93 in patientswith noWMPs up to 1.11 (mild), 1.17 (moderate) and
1.76 (severe) (P0.0001). Mean annual primary care consultations were 1.7 (no
WMPs), 2.0 (mild), 1.9 (moderate) and 2.9 (severe) (P0.0001). Similar patterns of
health resource utilisation were observed in time spent with urologists – 0.1 (no
WMPs), 0.2 (mild), 0.3 (moderate) and 0.6 (severe) (P0.0001), and time spent with
physiotherapists (2.0, 4.7, 6.9 and 9.9 respectively, P0.0001). Similar trends were
observed with use of wheelchair, walking frame, walking stick and ambulatory
support from family and friends. CONCLUSIONS: Increased WMPs are associated
with increased use of healthcare resources among MS patients. These results sug-
gest that functional impairment due to mobility problems, including walking, may
exert additional economic burden. Therapies that specifically improve patients’
walking and mobility could have a positive socio-economic impact.
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BACKGROUND: Among patients with multiple sclerosis (MS), increased disease
severity of disease is associatedwith increased burden of caregiving and decreased
employment status. Specific effects of walking/mobility problems (WMPs) on care-
giving requirements and employment status are unknown. OBJECTIVES: Examine
the relationship between presence/severity of WMPs in MS patients on: formal
(paid professional) and informal (friends/family) caregiving; and indirect costs re-
lated to employment status.METHODS:Data were obtained from a cross-sectional
study of 340 neurologists in France, Germany, Italy, Spain and UNITED KINGDOM.
Neurologists completed records on the next 10-12 consulting MS patients. Among
3572 patients, 2111 completed a questionnaire indicating their level ofWMPs: none
(n1342), mild (n271), moderate (n314), severe (n184). Chi-square with Bon-
ferroni-adjusted Fisher’s-Exact tests assessed the relationship betweenWMPs and
level of caregiving required and employment status. ANOVA with Bonferroni-cor-
rected t-tests assessed the relationship between WMPs and annual days off-work.
RESULTS: Analysis showed a positive association between severity of WMPs and
caregiver requirement (P0.0001). Patients reporting severe WMPs required more
formal care (50%) compared with no WMPs (10%), mild (11%) and moderate (23%)
(P0.0001). A similar pattern was observed for informal care; noWMPS (11%), mild
(14%), moderate (28%), severe (31%) (P0.0001). Mean annual days off-work was
21(s.d.43) for noWMPs compared with 74(s.d.121) for severeWMPs (P0.0001). 12%
of patients with no WMPs had reduced weekly work-hours compared with 22%-
26% among those with WMPs (P0.0001). Only 7% of patients with no WMPs had
given upwork altogether comparedwith 29% ofmoderate and 38% of patients with
severe WMPs (P0.0001). CONCLUSIONS: These analyses highlight an increased
need for formal care amongMSpatientswithWMPs, especially those inwhom they
are severe. A negative impact in employment status is associated with severity of
WMPs. Given thatwalking problems impose a strain onMS patients, friends/family
and health/social care authorities, therapeutic options that improveWMPs should
be a public health priority.
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HUMANISTIC AND ECONOMIC BURDEN IN TUBEROUS SCLEROSIS COMPLEX
WITH NEUROLOGICAL MANIFESTATIONS: SYSTEMATIC REVIEW
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OBJECTIVES:Toassess currentunderstandingofhumanistic andeconomicburdenof
tuberous sclerosis complex (TSC), a rare progressive genetic disorder characterized by
benign tumors in multiple organ systems. Common neurological manifestations in-
clude brain lesions, epilepsy, seizures, and mental retardation. METHODS: Using
specified keywords related to TSC, we systematically searched MEDLINE- and EM-
BASE-indexed, English-language literature published between 5/2000 - 5/2010, and
non-indexedmaterials from governmental or professional organizations. Included
articles pertained to clinical, economic and humanistic burden of TSC in humans.
Excluded articles were molecular biology and genetic studies, and, to eliminate
lower-value studies, case reports and studies enrolling20 TSCpatients.RESULTS:
One hundred and nineteen articles were included, with 115 on clinical burden.
While no therapies prevent disease progression, treatment of TSC and its neuro-
logical manifestations remains poorly defined by guidelines and focuses on symp-
tom management. Caregiver burden is substantial, as many parents experience
stress related to children’s basic needs, psychiatric diagnoses, low intelligence,
behavioral problems, and seizures. While two survey studies explore caregiver
burden, there are no studies on health-related quality of life in TSC patients. Also
absent are cost of treatment and resource use associatedwith TSC,which are likely
substantial for symptomatic subependymal giant cell astrocytomas (SEGAs) and
medically refractory epilepsy that often require surgical resection to control symp-
toms and disease progression. There are no cost-effectiveness analyses or studies
of indirect costs. Two analyses of the cost of genetic testing suggest that TSC is too
rare to recommend population-wide screening. CONCLUSIONS: Few available data
quantify the humanistic and economic burden of TSC. As a lifelong condition with
disabling neurological manifestations and unmet clinical needs, the care and costs
associated with TSC burden patients, caregivers, and society. Future research
should determine total cost of disease, including probable high indirect costs of
caregiver time and lost productivity.
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HEALTHCARE UTILIZATION AND COSTS AMONG AD PATIENTS WITH AND
WITHOUT DYSPHAGIA
Gabriel S, Tian H, Kim E, Kahler KH
Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA
OBJECTIVES: To assess whether healthcare utilization and associated costs dif-
fered among Alzheimer’s patients with and without dysphagia. METHODS: Data
were taken from MarketScan Medicare Commercial Claims and Encounters and
MarketScan Medicare Supplemental and Coordination of Benefits datasets. Pa-
tients with a diagnosis of Alzheimer’s disease (AD) with and without a diagnosis of
dysphagia between 1/01/06-12/31/08 were included. Number of ER visits, outpa-
tient visits and hospitalizations, as well as all-cause total healthcare, outpatient,
inpatient, ER, and outpatient prescription drug costs, were assessed. Cholinest-
erase inhibitor usage was assessed. All variables were measured in the one year
post initial diagnosis of AD, at the patient level. Bivariate analyses were conducted
using chi-square test (for categorical measures) and t-tests (for continuous mea-
sures) to examine differences between AD patients with and without dysphagia.
RESULTS: A total of 95,817 Alzheimer’s patients were included in the analysis:
11,748 (13%) with dysphagia, and 84,069 (87%) without dysphagia. Mean age of AD
patients was 79 (std10); 61% were female. Dysphagic patients had a significantly
higher number of ER visits (1.8 vs. 1.0), outpatient visits (16.2 vs. 11.4) and hospi-
talizations (11.3 vs. 4.3). Total annual healthcare costs ($12,627 vs. $8,031), outpa-
tient ($1,488 vs. $1,039), inpatient ($6,543 vs. $2,705), and ER costs ($700 vs. $414)
were significantly higher for dysphagic patients (p0.01 in all cases). No significant
difference was found for outpatient prescription costs. Significantly fewer
dysphagic patients used cholinesterase inhibitor (ChEI) therapy (39% vs. 51%;
p0.01), or patch formulation (2.5% vs. 3.4%; p0.01), compared with non-
dysphagic patients. CONCLUSIONS: Dysphagia is not uncommon among patients
withAlzheimer’s disease. Alzheimer’s patientswith dysphagia have higher health-
care utilization and costs, compared with non-dysphagic patients. In both groups,
treatment with cholinesterase inhibitors was low.
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ESTIMATED COSTS OF FINGOLIMOD MONITORING FOR INDIVIDUALS WITH
RELAPSING REMITTING MULTIPLE SCLEROSIS
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OBJECTIVES: To develop a tool to estimate the first-year per member and total
health plan costs associated with fingolimodmonitoring recommended by its Risk
Evaluation andMitigation Strategy (REMS).METHODS:Datawere incorporated into
an interactive tool designed to allow a health plan to estimate their costs for mon-
itoring. The prevalence of MS was based on the literature. Default values for the
proportion of patients treated with immunomodulators and fingolimod were as-
sumed and set at 95% and 1%, respectively. Current Procedural Terminology (CPT)
codes corresponding to recommended monitoring procedures were identified.
Charges associated with each CPT code were identified using software designed to
build a physician fee schedule based on Medicare charges and default values were
set at 150% of Medicare charges. In cases where the REMS recommended that all
patients undergo certainmonitoring, default values were set at 100% for thatmon-
itoring. In cases where the REMS recommended individuals with specific charac-
teristics undergo monitoring, a database analysis identifying all individuals with a
diagnosis of MS in the i3 InVision DataMart (Ingenix, Eden Prairie, MN) was used to
estimate the proportion of patients who may require that specific monitoring.
RESULTS: The tool yielded average per patient and health plan costs expectedwith
fingolimod monitoring. The tool conservatively estimates that the average per
member first-year monitoring cost for fingolimod is $1905. Based on the default
values, the estimated annual costs of fingolimod monitoring for a million member
health plan is $18,458. The initial cardiacmonitoring was the largest contributor to
the total cost of monitoring. CONCLUSIONS: Estimating the anticipated economic
impact of fingolimod monitoring, based on its REMS, allows health plans to more
closely assess the total cost of fingolimod therapy. This tool allows health plans to
individualize inputs to estimate the plan-specific economic impact of fingolimod
monitoring.
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